

PB 97 of 2024

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 9)

National Health Act 1953

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 98C(1) of the *National Health Act 1953*.

Dated 27 September 2024

NIKOLAI TSYGANOV

Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division

1 Name 1 2 Commencement 1 3 Authority 1 4 Schedules 1

Schedule 1—Amendments

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019

1

1 Name

- (1) This instrument is the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 9).
- (2) This instrument may also be cited as PB 97 of 2024.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	1 October 2024	1 October 2024

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 98C(1) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)

[1] Schedule 1, after entry for Azithromycin

110	se	vt.
u	se.	ıι.

[2] Schedule 4, entry for Estradiol

omit:

Estradiol	Transdermal patches 2 mg, 4
Estradiol	Transdermal patches 3.8 mg, 4
Estradiol	Transdermal patches 5.7 mg, 4
Estradiol	Transdermal patches 7.6 mg, 4

- [3] Schedule 4, omit entry for Fluorometholone
- [4] Schedule 4, omit entry for Larotrectinib
- [5] Schedule 4, after entry for Timolol in the form Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL (S19A)

insert:

Timolol	Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL -
	(Timoptol-LA) (S19A)